211At-BC8-B10 and Donor Stem Cell Transplant in Treating Relapsed or Refractory AML, ALL, or Myelodysplastic Syndrome

Conditions:   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Chronic Myelomonocytic Leukemia;   Myeloproliferative Neoplasm, Unclassifiable Interventions:   Biological: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total-Body Irradiation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Bone Marrow Transplantation;   Drug: Tacrolimus;   Drug: My cophenolate Mofetil;   Drug: Sirolimus;   Biological: Granulocyte Colony-Stimulating Factor Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials